SOPH SOPHiA GENETICS, Inc.
SOPHiA GENETICS, Inc. (SOPH) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 84% planned / 16% discretionary
Largest single sale: $65.1K.
Where they traded
Last open-market purchase: June 5, 2026 , by CARDOZA GEORGE .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| CARDOZA GEORGE | Chief Financial Officer | Sell 10b5-1 | 774 | $8.33 | $6.4K | 308,318 −0.3% of holding | |
| Muken Ross | Chief Executive Officer | Sell 10b5-1 | 422 | $8.33 | $3.5K | 670,229 −0.1% of holding | |
| Menu Philippe | Chief Medical Officer | Sell | 5,000 | $7.88 | $39.4K | 208,387 −2.3% of holding | |
| Xu Zhenyu | Chief Scientific Officer | Sell 10b5-1 | 4,000 | $7.88 | $31.5K | 552,887 −0.7% of holding | |
| Van Well Daan | Chief Legal Officer | Sell 10b5-1 | 6,168 | $7.63 | $47.1K | 338,884 −1.8% of holding | |
| Camblong Jurgi | Executive Chairman | Sell 10b5-1 | 8,500 | $7.66 | $65.1K | 3,435,822 −0.2% of holding | |
| HIBBS KATHY L | Director | Sell 10b5-1 | 6,250 | $8.13 | $50.8K | 96,992 −6.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.